Navigation Links
EpiCept Reports Second Quarter 2013 Operating and Financial Results
Date:7/31/2013

n to act as vascular disruption agents in a variety of solid tumors.

About Immune Pharmaceuticals Ltd.Immune Pharmaceuticals Ltd. is an Israel- and U.S.-based biopharmaceutical company focused on the development of next-generation antibody therapeutics to address unmet medical needs in the treatment of inflammatory diseases and cancer. Immune licensed worldwide rights for systemic indications of bertilimumab from iCo Therapeutics in June 2011, while iCo retained rights to all ophthalmic indications. iCo originally licensed exclusive worldwide rights to bertilimumab in 2006 from MedImmune Limited (formerly known as Cambridge Antibody Technology Limited), the global biologics unit of AstraZeneca. Additionally, Immune has licensed from Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem, injectable applications of the antibody nanoparticle conjugate technology (NanomAbs®) developed by Prof. Shimon Benita.  For more information, visit the Immune website at www.immunepharmaceuticals.com.

Forward-Looking Statements This news release and any oral statements made with respect to the information contained in this news release contain forward-looking statements.  You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal" or the negative of those words or other comparable words to be uncertain and forward-looking.  Such forward-looking statements include statements that express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on our current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from histo
'/>"/>

SOURCE EpiCept Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
2. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
3. Interleukin Genetics Reports Third Quarter 2011 Financial Results
4. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
5. Nile Therapeutics Reports 2011 Third Quarter Financial Results
6. Pharmasset Reports Fiscal Year End 2011 Financial Results
7. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
8. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
9. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
10. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
11. Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently ... Supplements Pre-Conference seminar on probiotics in San Diego, CA. ... education conference for health care professionals. This year’s pre-conference seminar ... probiotics in health. Dr. Leyer spoke about the emerging topics ...
(Date:1/22/2015)... BRUNSWICK , Nueva Jersey , 22 de ... Award for Biomedical Research abre hoy su llamada a ... personas cuya investigación científica ha hecho, o tiene el ... la salud humana. Las nominaciones se aceptarán hasta el ...
(Date:1/22/2015)...  Derma Sciences, Inc. (Nasdaq: DSCI ), ... care, announces that AMNIOEXCEL® and AMNIOMATRIX®, amniotic allografts ... the Premier, Inc. Regenerative Skin Grafting contract portfolio. ... and AMNIOMATRIX® product lines, which continue to be ...
(Date:12/24/2014)... AUSTIN, Texas , Dec. 24, 2014  Vermillion, ... focused on gynecologic disease, announced today that the ... investors including Oracle Investment Management, Jack W. ... directors. Total proceeds were $10.5 million, before offering ...
Breaking Biology Technology:El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... 27 Alfacell Corporation (OTC Bulletin Board: ACEL) today ... the U.S. Food and Drug Administration (FDA) to discuss ... the ONCONASE rolling New Drug Application (NDA) for the ... the pre-NDA meeting, the FDA provided guidance to the ...
... for Tuesday, February 3, 2009 SAN DIEGO, Jan. 27 ... announced today that the Company will report its fourth ... market closes on Tuesday, February 3, 2009. Neurocrine will ... discuss its financial results and provide a Company update ...
... in Shortest Period of TimeWASHINGTON, Jan. 27 ... in targeted therapies that utilize personalized medicine to ... by the Deloitte Center for Health Solutions found ... to produce a positive return on investment across ...
Cached Biology Technology:Alfacell Provides ONCONASE(R) NDA Submission Update 2Alfacell Provides ONCONASE(R) NDA Submission Update 3Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2008 Financial Results 2Adoption of Personalized Medicine May Yield Significant ROI; Time to Achieve Benefit Varies Among U.S. Health Care Stakeholders, According to Deloitte Report 2Adoption of Personalized Medicine May Yield Significant ROI; Time to Achieve Benefit Varies Among U.S. Health Care Stakeholders, According to Deloitte Report 3Adoption of Personalized Medicine May Yield Significant ROI; Time to Achieve Benefit Varies Among U.S. Health Care Stakeholders, According to Deloitte Report 4
(Date:12/19/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ) ... Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology ... http://photos.prnewswire.com/prnh/20130307/600769 Following the acquisition ... reading feature with the iPhone 5S. It is currently ...
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , the ... the post-password and Internet of Things era, today announced ... The venture round was led by Metamorphic Ventures with ... Venture Partners, VegasTechFund, and others.  LaunchKey has raised $4 ...
(Date:12/17/2014)... YORK , Dec. 15, 2014  HITLAB SM ... (GCP) audit to confirm its adherence to current U.S. ... HITLAB to conduct regulated smart device and smart phone ... and research quality. "HITLAB is determined to ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... disorders are almost five times more common among boys than ... $15 million National Institutes of Health (NIH) grant awarded to ... (ACE) research program. Led by principal investigator Kevin ... is part of a $100 million National Institutes of Health ...
... - Influenza outbreaks in the United States typically begin ... spread in seasonal waves across geographic zones. But the ... to the next has baffled scientists. In a ... Obscure Consequence," Elena Naumova, Ph.D., professor of civil and ...
... SAN FRANCISCO, Sept. 6, 2012 -- After last year,s accidental ... State researchers are conducting an elaborate experiment to learn more ... are tagging infected bees with tiny radio trackers, and monitoring ... hive on top of the Hensill Hall biology building on ...
Cached Biology News:Influenza research: Can dynamic mapping reveal clues about seasonality? 2SF State biologists tag 'zombees' to track their flight 2SF State biologists tag 'zombees' to track their flight 3
... Monoclonal Mouse Antibody to Cytokeratin 5 ... is a high molecular weight, basic type ... and the superficial cell layers of stratified ... epithelia and in mesothelial cells and mesothelioma. ...
...
Aldolase A (N-15)...
Bovine Renal Artery Endothelial Cells (BRAEC) (>500,000 cells)...
Biology Products: